JERSEY CITY – November 02, 2026 -- ABVC BioPharma (NASDAQ: ABVC) has closed a private placement of original issue discount senior convertible promissory notes that generated approximately $3.39 million in gross proceeds, before placement agent fees and offering expenses, WallachBeth Capital LLC announced.

Notes carry $4.1 million principal and a June 2027 maturity

The 17.5% OID Notes have an aggregate principal amount of $4,106,060 and mature on June 30, 2027. Investors in the securities purchase agreement are institutional and other accredited investors.

The notes become convertible into ABVC common stock after the eight-month anniversary of issuance. The conversion price is 85% of the average of the three VWAPs for the three trading days immediately before conversion, subject to a floor price and adjustments set out in the notes.

ABVC earmarks $625,000 for Lind Global Fund II settlement

ABVC plans to use net proceeds for general working capital, funding of its subsidiaries, and a $625,000 settlement payment to Lind Global Fund II LP under a definitive release and settlement agreement. The company said the payment is expected to satisfy the specified outstanding payment claims.

Subsidiary platforms span CNS, oncology, ophthalmic devices and contract manufacturing

ABVC said the financing supports its strategy of advancing a pharmaceutical and medical-device portfolio through licensing, subsidiary development and independent financing. The company has set up four dedicated platforms:

• AiBtl BioPharma Inc. for central nervous system drug programs
• OncoX BioPharma for oncology
• ForSeeCon Eye for ophthalmic medical-device development and commercialization
• BioKey (Cayman), Inc. for contract pharmaceutical development and manufacturing, plus an AI Biotechnology Innovation Platform

ABVC is targeting licensing revenues, milestone payments, future royalties and equity value through these arrangements. It continues to evaluate strategic financing and capital-market options for the affiliated businesses.

WallachBeth acts as placement agent; securities remain unregistered

WallachBeth Capital, Inc. served as placement agent. Hunter Taubman Fischer & Li LLC advised ABVC, and Sichenzia Ross Ference Carmel LLP advised the placement agent.

The notes and the underlying conversion shares are not registered under the Securities Act of 1933 or any state securities laws. They cannot be offered or sold in the United States without registration or an applicable exemption. ABVC will file a Current Report on Form 8-K with the U.S. Securities and Exchange Commission, with the definitive transaction documents attached as exhibits.